UA100120C2 - 5,6-dihydro-1h-pyridin-2-one compounds - Google Patents

5,6-dihydro-1h-pyridin-2-one compounds

Info

Publication number
UA100120C2
UA100120C2 UAA200910844A UAA200910844A UA100120C2 UA 100120 C2 UA100120 C2 UA 100120C2 UA A200910844 A UAA200910844 A UA A200910844A UA A200910844 A UAA200910844 A UA A200910844A UA 100120 C2 UA100120 C2 UA 100120C2
Authority
UA
Ukraine
Prior art keywords
compounds
pyridin
dihydro
hepatitis
virus
Prior art date
Application number
UAA200910844A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чин Вьет Тран
Фрэнк Рубсам
Дуглас Эрик Мерфи
Питер Ес. Драгович
Юэфен Джоу
Лиджиан Чен
Дэйвид Куцера
Фриц Блаттер
Мартин Виртелхаус
Original Assignee
Анадис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA100120(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Анадис Фармасьютикалз, Инк. filed Critical Анадис Фармасьютикалз, Инк.
Publication of UA100120C2 publication Critical patent/UA100120C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается соединений 5,6-дигидро-1H-пиридин-2-ону и фармацевтических композиций, которые содержат такие соединения, полезные в лечении инфекции вируса гепатита С.
UAA200910844A 2007-04-03 2008-02-04 5,6-dihydro-1h-pyridin-2-one compounds UA100120C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90747807P 2007-04-03 2007-04-03

Publications (1)

Publication Number Publication Date
UA100120C2 true UA100120C2 (en) 2012-11-26

Family

ID=39831340

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910844A UA100120C2 (en) 2007-04-03 2008-02-04 5,6-dihydro-1h-pyridin-2-one compounds

Country Status (23)

Country Link
US (6) US7939524B2 (ru)
EP (1) EP2129224B1 (ru)
JP (2) JP5739662B2 (ru)
KR (1) KR101542516B1 (ru)
CN (2) CN101677563B (ru)
AR (1) AR065927A1 (ru)
AU (1) AU2008237364B2 (ru)
BR (1) BRPI0809685A2 (ru)
CA (1) CA2682584C (ru)
CL (1) CL2008000959A1 (ru)
EA (1) EA017685B1 (ru)
ES (1) ES2578302T3 (ru)
HK (2) HK1137119A1 (ru)
IL (2) IL201312A (ru)
MX (1) MX2009010564A (ru)
MY (1) MY157961A (ru)
NZ (1) NZ580445A (ru)
PE (1) PE20090220A1 (ru)
TN (1) TN2009000398A1 (ru)
TW (2) TWI481588B (ru)
UA (1) UA100120C2 (ru)
WO (1) WO2008124450A1 (ru)
ZA (1) ZA200907673B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5306194B2 (ja) * 2006-06-22 2013-10-02 アナディス ファーマシューティカルズ インク ピロ［１，２−ｂ］ピリダジノン化合物
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
CN102316871B (zh) 2008-06-10 2014-06-04 安那迪斯药品股份有限公司 [1，2，4]噻二嗪1，1-二氧化合物
WO2010042834A1 (en) 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
TW201026675A (en) * 2008-10-09 2010-07-16 Anadys Pharmaceuticals Inc 5,6-dihydro-1H-pyridin-2-one compounds
MX2012004922A (es) 2009-10-28 2012-05-29 Anadys Pharmaceuticals Inc Compuesto de 5,6-dihidro-1h-piridin-2-ona deuterados.
JP5536229B2 (ja) 2009-12-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ併用療法
WO2012158271A1 (en) 2011-04-06 2012-11-22 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds as antiviral agents
AU2012268119B2 (en) * 2011-06-07 2017-03-02 Anadys Pharmaceuticals, Inc. [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
CA2875541A1 (en) * 2012-06-12 2013-12-19 Patrick F. Smith Combination of therapeutic agents for treating hcv infection
WO2014108806A2 (en) 2013-01-14 2014-07-17 F. Hoffmann-La Roche Ag A novel process for the preparation of n-(4-nitro-2-sulfamoly-phenyl)-malonamic acid methyl ester and n-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester
HUE052178T2 (hu) * 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
WO2016130043A1 (ru) * 2015-02-13 2016-08-18 Александ Васильевич ИВАЩЕНКО Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
EP3464318B1 (en) 2016-06-02 2021-04-21 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
JP7435515B2 (ja) * 2021-03-17 2024-02-21 株式会社村田製作所 部品収容装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171361A (en) * 1977-03-31 1979-10-16 Eli Lilly And Company 1-Substituted-3-amino-6,7-dialkoxy-1H-1,2,4-benzothiadiazine-1-oxides
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2004509066A (ja) 2000-05-10 2004-03-25 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
PT1560827E (pt) * 2002-11-01 2011-03-17 Abbott Lab Agentes anti-infecciosos
WO2004041818A1 (en) 2002-11-01 2004-05-21 Abbott Laboratories Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CA2561305C (en) * 2004-03-24 2013-07-30 Bharat Lagu Tetrahydro-indazole cannabinoid modulators
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JP4624419B2 (ja) 2004-08-23 2011-02-02 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性へテロ環化合物
US7425552B2 (en) 2004-12-17 2008-09-16 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
WO2006093801A1 (en) * 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
JPWO2006115221A1 (ja) 2005-04-21 2008-12-18 日本新薬株式会社 フタラジノン誘導体及びその医薬
JP2008540370A (ja) 2005-05-04 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
WO2008051637A2 (en) 2006-06-22 2008-05-02 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
JP5306194B2 (ja) * 2006-06-22 2013-10-02 アナディス ファーマシューティカルズ インク ピロ［１，２−ｂ］ピリダジノン化合物
WO2008073987A1 (en) 2006-12-12 2008-06-19 Anadys Pharmaceuticals, Inc. Saturated fused [1,2-b] pyridazinone compounds
TW200840572A (en) * 2006-12-12 2008-10-16 Anadys Pharmaceuticals Inc 5,6-dihydro-1H-pyridin-2-one compounds
US20080188466A1 (en) 2006-12-21 2008-08-07 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
WO2008082725A1 (en) 2006-12-29 2008-07-10 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
US20080227774A1 (en) 2007-03-15 2008-09-18 Frank Ruebsam 5,5-disubstituted-indolizinone compounds
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US7834009B2 (en) * 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

Also Published As

Publication number Publication date
JP2015134783A (ja) 2015-07-27
US8765741B2 (en) 2014-07-01
EA017685B1 (ru) 2013-02-28
EP2129224B1 (en) 2016-03-30
TW201431830A (zh) 2014-08-16
WO2008124450A1 (en) 2008-10-16
PE20090220A1 (es) 2009-03-12
TN2009000398A1 (en) 2010-12-31
CN101677563B (zh) 2014-06-25
CA2682584C (en) 2017-03-14
IL225694A0 (en) 2013-06-27
US20100034773A1 (en) 2010-02-11
US20140031346A1 (en) 2014-01-30
TWI481588B (zh) 2015-04-21
EP2129224A4 (en) 2011-01-05
JP2010523586A (ja) 2010-07-15
IL201312A (en) 2015-05-31
CL2008000959A1 (es) 2008-11-03
ES2578302T3 (es) 2016-07-22
KR101542516B1 (ko) 2015-08-06
JP5934403B2 (ja) 2016-06-15
TW200906829A (en) 2009-02-16
CN104086540A (zh) 2014-10-08
EA200970916A1 (ru) 2010-04-30
US20110166344A1 (en) 2011-07-07
ZA200907673B (en) 2014-04-30
TWI427079B (zh) 2014-02-21
KR20090127437A (ko) 2009-12-11
MY157961A (en) 2016-08-30
CN101677563A (zh) 2010-03-24
JP5739662B2 (ja) 2015-06-24
US20120302744A1 (en) 2012-11-29
HK1137119A1 (zh) 2010-07-23
US7939524B2 (en) 2011-05-10
CA2682584A1 (en) 2008-10-16
IL201312A0 (en) 2010-05-31
US20150065492A1 (en) 2015-03-05
AU2008237364B2 (en) 2014-03-06
EP2129224A1 (en) 2009-12-09
AU2008237364A1 (en) 2008-10-16
US20120130068A1 (en) 2012-05-24
BRPI0809685A2 (pt) 2016-09-27
US9156832B2 (en) 2015-10-13
CN104086540B (zh) 2017-04-12
AR065927A1 (es) 2009-07-08
IL225694A (en) 2016-08-31
HK1201822A1 (en) 2015-09-11
US8101800B2 (en) 2012-01-24
US8236948B2 (en) 2012-08-07
NZ580445A (en) 2012-01-12
US8546602B2 (en) 2013-10-01
MX2009010564A (es) 2009-10-26

Similar Documents

Publication Publication Date Title
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
TW200635596A (en) Pyridazinone compounds
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
HK1123733A1 (en) Viral hepatitis treatment
WO2007150001A8 (en) Pyrro[1,2-b]pyridazinone compounds
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
WO2008127364A3 (en) Antiviral compounds and use thereof
EA201390538A1 (ru) Противовирусные соединения
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
WO2008115281A3 (en) Compounds for treating viral infections
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
IL196815A0 (en) Hepatitis c virus inhibitors
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
WO2008144500A3 (en) 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
WO2008051637A3 (en) Pyridazinone compounds
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
UY31888A (es) Compuestos de 1,1-dióxido de [1,2,4,]tiadiazina